{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T10:12:21Z","timestamp":1760004741568,"version":"build-2065373602"},"reference-count":22,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.diagmicrobio.2020.115126","type":"journal-article","created":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T01:58:59Z","timestamp":1594173539000},"page":"115126","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Assessment of invitrosynergy of daptomycin or vancomycin plus ceftaroline for daptomycin non-susceptible Staphylococcus aureus"],"prefix":"10.1016","volume":"98","author":[{"given":"Mary A.","family":"Hutton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayesha","family":"Sundaram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary B.","family":"Perri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus J.","family":"Zervos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica S.","family":"Herc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2020.115126_bb0005","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1056\/NEJMoa1011138","article-title":"Genetic basis for in vivo daptomycin resistance in enterococci","volume":"365","author":"Arias","year":"2011","journal-title":"NEJM"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2020.115126_bb0010","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1093\/jac\/dku322","article-title":"Vancomycin plus ceftaroline shows potent in vitro synergy and was successfully utilized to clear persistent daptomycin-non-susceptible MRSA bacteraemia","volume":"70","author":"Barber","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2020.115126_bb0015","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1749-6632.2012.06819.x","article-title":"Mechanisms of daptomycin resistance in Staphylococcus aureus: role of the cell membrane and cell wall","volume":"1277","author":"Bayer","year":"2014","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2020.115126_bb0020","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ijantimicag.2013.10.001","article-title":"dltA overexpression: a strain-independent keystone of daptomycin resistance in methicillin-resistant Staphylococcus aureus","volume":"43","author":"Cafiso","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2020.115126_bb0025","series-title":"Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard--Tenth Edition. CLSI document M07-A10","first-page":"8","author":"CLSI","year":"2015"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2020.115126_bb0030","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/cid\/cir340","article-title":"Use of antistaphylococcal b-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding","volume":"53","author":"Dhand","year":"2011","journal-title":"CID"},{"key":"10.1016\/j.diagmicrobio.2020.115126_bb0035","series-title":"Antibiotics in laboratory medicine","first-page":"432","article-title":"Antimicrobial combinations","author":"Eliopoulos","year":"1991"},{"issue":"10","key":"10.1016\/j.diagmicrobio.2020.115126_bb0040","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1007\/s10096-017-2999-3","article-title":"Down-regulation of the two-component system and cell-wall biosynthesis-related genes was associated with the reversion to daptomycin susceptibility in daptomycin non-susceptible methicillin-resistant Staphylococcus aureus","volume":"36","author":"Iwata","year":"2017","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2020.115126_bb0045","first-page":"1","article-title":"Clinical Practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"53","author":"Liu","year":"2011","journal-title":"CID"},{"key":"10.1016\/j.diagmicrobio.2020.115126_bb0050","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1172\/JCI18535","article-title":"Antimicrobial resistance: the example of Staphylococcus aureus","volume":"111","author":"Lowy","year":"2003","journal-title":"J Clin invest"},{"key":"10.1016\/j.diagmicrobio.2020.115126_bb0055","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1128\/JCM.41.11.5113-5120.2003","article-title":"Pulsed-field gel electrophoresis typing of oxacillin-resistant Staphylococcus aureus isolates from the United States: establishing a national database","volume":"41","author":"McDougal","year":"2003","journal-title":"J Clin Microbiol"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2020.115126_bb0060","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1128\/AAC.00432-10","article-title":"VraSR two-component regulatory system contributes to mprF-mediated decreased susceptibility to daptomycin in in vivo-selected clinical strains of methicillin-resistant Staphylococcus aureus","volume":"56","author":"Mehta","year":"2012","journal-title":"AAC"},{"year":"1999","series-title":"Methods for Determining Bactericidal Activity of Antimicrobial Agents; Approved Guideline. NCCLS document M26-A","author":"NCCLS","key":"10.1016\/j.diagmicrobio.2020.115126_bb0065"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2020.115126_bb0070","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/jac\/dkp377","article-title":"Limitations of antibiotic options for invasive infections caused by methicillin-resistant Staphylococcus aureus: is combination therapy the answer?","volume":"65","author":"Nguyen","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2020.115126_bb0075","doi-asserted-by":"crossref","first-page":"5296","DOI":"10.1128\/AAC.00797-12","article-title":"Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activity","volume":"56","author":"Rose","year":"2012","journal-title":"AAC"},{"issue":"10","key":"10.1016\/j.diagmicrobio.2020.115126_bb0080","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.clinthera.2014.05.061","article-title":"Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline","volume":"36","author":"Sakoulas","year":"2014","journal-title":"Clin Ther"},{"key":"10.1016\/j.diagmicrobio.2020.115126_bb0085","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/infdis\/131.3.245","article-title":"Antibiotic combinations in the treatment of experimental Staphylococcus aureus infection","volume":"131","author":"Steigbigel","year":"1975","journal-title":"J Infect Dis"},{"year":"2018","series-title":"Molecular Epidemiology of Daptomycin Non-Susceptibility in Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia","author":"Sundaram","key":"10.1016\/j.diagmicrobio.2020.115126_bb0090"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2020.115126_bb0095","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/phar.2070","article-title":"Association of higher daptomycin dose (7 mg\/kg or greater) with improved survival in patients with methicillin-resistant Staphylococcus aureus bacteremia","volume":"38","author":"Timbrook","year":"2018","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.diagmicrobio.2020.115126_bb0100","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/nyas.12948","article-title":"Mechanisms of drug resistance: daptomycin resistance","volume":"1354","author":"Tran","year":"2015","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2020.115126_bb0105","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1128\/AAC.02354-12","article-title":"Novel combinations of vanomycin plus ceftaroline or oxacillin against methicillin-resistant vancomyin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA","volume":"57","author":"Werth","year":"2013","journal-title":"AAC"},{"key":"10.1016\/j.diagmicrobio.2020.115126_bb0110","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1128\/AAC.00088-14","article-title":"Evaluation of ceftaroline, vancomycin, daptomycin, or ceftaroline plus daptomycin against daptomycin-nonsusceptible methicillin resistant Staphylococcus aureus in an in vitro pharmacokinetic\/pharmacodynamic model of simulated endocardial vegetations","volume":"58","author":"Werth","year":"2014","journal-title":"AAC"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889320305034?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889320305034?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:54:31Z","timestamp":1760003671000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889320305034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S0732889320305034"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2020.115126","relation":{},"ISSN":["0732-8893"],"issn-type":[{"type":"print","value":"0732-8893"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of invitrosynergy of daptomycin or vancomycin plus ceftaroline for daptomycin non-susceptible Staphylococcus aureus","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2020.115126","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115126"}}